119 related articles for article (PubMed ID: 18462248)
1. The misuse of the faecal occult blood test under the lower gastrointestinal two week wait rule.
Shaw AG; Lund JN; Longman C; Tierney GM; Goddard AF
Colorectal Dis; 2009 Jan; 11(1):94-6. PubMed ID: 18462248
[TBL] [Abstract][Full Text] [Related]
2. Two-week wait symptoms are prevalent in screened patients with a positive faecal occult blood test but do not predict cancer.
Vaughan-Shaw PG; Cutting J; Borley N; Brooklyn T; Wheeler JM
Colorectal Dis; 2014 Jan; 16(1):40-7. PubMed ID: 24103034
[TBL] [Abstract][Full Text] [Related]
3. Inappropriate use of the faecal occult blood test outside of the National Health Service colorectal cancer screening programme.
Peacock O; Watts ES; Hanna N; Kerr K; Goddard AF; Lund JN
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1270-5. PubMed ID: 22872076
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
McDonald R; Tomlins A; Smith S; Harmston C
J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
[TBL] [Abstract][Full Text] [Related]
5. Referral of patients with iron deficiency anaemia under the lower gastrointestinal two-week wait rule.
Shaw AG; Simpson J; Tierney G; Goddard AF; Reynolds JR; Lund JN
Colorectal Dis; 2008 Mar; 10(3):294-7. PubMed ID: 17764534
[TBL] [Abstract][Full Text] [Related]
6. Immunological faecal occult blood testing: a discriminatory test to identify colorectal cancer in symptomatic patients.
Kaul A; Shah A; Magill FH; Hawkins SA; Skaife P
Int J Surg; 2013; 11(4):329-31. PubMed ID: 23459187
[TBL] [Abstract][Full Text] [Related]
7. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test.
Rodríguez-Alonso L; Rodríguez-Moranta F; Ruiz-Cerulla A; Lobatón T; Arajol C; Binefa G; Moreno V; Guardiola J
Dig Liver Dis; 2015 Sep; 47(9):797-804. PubMed ID: 26055489
[TBL] [Abstract][Full Text] [Related]
8. Symptoms do not predict colorectal cancer in an FOB screened population.
Saldanha JD; Moug SJ; Linton K; Diament RH
Scott Med J; 2013 May; 58(2):95-8. PubMed ID: 23728754
[TBL] [Abstract][Full Text] [Related]
9. A population-based audit of the clinical use of faecal occult blood testing in primary care for colorectal cancer.
Gillberg A; Ericsson E; Granstrom F; Olsson LI
Colorectal Dis; 2012 Sep; 14(9):e539-46. PubMed ID: 22738077
[TBL] [Abstract][Full Text] [Related]
10. Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review.
Narula N; Ulic D; Al-Dabbagh R; Ibrahim A; Mansour M; Balion C; Marshall JK
Can J Gastroenterol Hepatol; 2014 Sep; 28(8):421-6. PubMed ID: 25014182
[TBL] [Abstract][Full Text] [Related]
11. How often is a positive faecal occult blood test the result of coeliac disease?
Logan RF; Howarth GF; West J; Shepherd K; Robinson MH; Hardcastle JD
Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1097-100. PubMed ID: 14501618
[TBL] [Abstract][Full Text] [Related]
12. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
[TBL] [Abstract][Full Text] [Related]
13. The two-week rule colorectal cancer pathway: an update on recent practice, the unsustainable burden on diagnostics and the role of faecal immunochemical testing.
Maclean W; Singh R; Mackenzie P; White D; Benton S; Stebbing J; Rockall T; Jourdan I
Ann R Coll Surg Engl; 2020 Apr; 102(4):308-311. PubMed ID: 32081023
[TBL] [Abstract][Full Text] [Related]
14. The 2-week wait referral system does not improve 5-year colorectal cancer survival.
Zafar A; Mak T; Whinnie S; Chapman MA
Colorectal Dis; 2012 Apr; 14(4):e177-80. PubMed ID: 21920007
[TBL] [Abstract][Full Text] [Related]
15. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
[TBL] [Abstract][Full Text] [Related]
16. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Clarke P; Jack F; Carey FA; Steele RJ
Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
[TBL] [Abstract][Full Text] [Related]
17. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines.
Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J
Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315
[TBL] [Abstract][Full Text] [Related]
18. The 2-week wait service: a UK tertiary colorectal centre's experience in the early identification of colorectal cancer.
Patel RK; Sayers AE; Seedat S; Altayeb T; Hunter IA
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1408-14. PubMed ID: 25244412
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial.
Howarth GF; Robinson MH; Jenkins D; Hardcastle JD; Logan RF
Am J Gastroenterol; 2002 Mar; 97(3):690-4. PubMed ID: 11926210
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
Berry DP; Clarke P; Hardcastle JD; Vellacott KD
Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
